This post-doctoral training grant application is a vital component of the Committee on Clinical Pharmacology and Pharmacogenomics, providing a mechanism for the training of young clinical investigators in preparation for an independent research career in Clinical Pharmacology. The Committee on Clinical Pharmacology and Pharmacogenomics is an interdepartmental unit comprised of faculty in the Departments of Anesthesia and Critical Care, Human Genetics, Medicine, Pediatrics, and Psychiatry, who have a shared interest and background in the principles of clinical pharmacology and pharmacogenomics. The training program also includes other faculty within the Biological Sciences Division who are involved in some aspect of clinical pharmacology and pharmacogenomics. The faculty jointly provide a core of knowledge regarding basic principles: pharmacodynamics and pharmacokinetics, drug disposition and metabolism, drug interactions, and various assay methodologies. Mark J. Ratain, M.D., who is Chairman of the Committee, directs the program along with Michael Maitland, M.D., Ph.D. who was appointed as the Associate Director of Fellow Education. An Executive Committee comprised of three other faculty representing the Committee's membership will advise them. Funding is requested to support the full-time research activities of 5 post- doctoral trainees each year. The majority of these trainees will have medical degrees and be board eligible in their area of specialty. A small number of trainees will hold Ph.D and/or Pharm.D. degrees The program will concentrate on research training that will take place under the supervision of the trainee's preceptor. Each trainee will be expected to enhance his/her education with formal coursework and participation in seminars, journal clubs and directed readings. The trainee will participate in activities such as the Clinical Pharmacology Consult Service, the Institutional Review Board, and the Pharmacy and Therapeutics Committee. A maximum of 10% effort (e.g. one-half day per week) will be allowed for clinical responsibilities in the area of the trainee's specialty. Upon completion of this program, the trainee is expected to become accomplished in basic research methodology, experimental design, and data interpretation and presentation, and be prepared for a competitive academic research career, as well as certification in Clinical Pharmacology.

Public Health Relevance

The training program in Clinical Pharmacology and Pharmacogenomics at the University of Chicago provides the intellectual environment, formal instruction, peer interaction and clinical experience necessary for trainees to acquire knowledge, skills, and attitudes essential to the practice of clinical pharmacology.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM007019-38
Application #
8668961
Study Section
Special Emphasis Panel (ZGM1)
Program Officer
Okita, Richard T
Project Start
1978-07-01
Project End
2015-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
38
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Chicago
State
IL
Country
United States
Zip Code
60637
Cavallo, Joel S; Ruiz, Nicholas A; de Wit, Harriet (2016) Extinction of Conditioned Responses to Methamphetamine-Associated Stimuli in Healthy Humans. Psychopharmacology (Berl) 233:2489-502
Alachkar, H; Fulton, N; Sanford, B et al. (2016) Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics J :
Nanda, Rita; Stringer-Reasor, Erica M; Saha, Poornima et al. (2016) A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer. Springerplus 5:947
Sweis, Randy F; Drazer, Michael W; Ratain, Mark J (2016) Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials. J Clin Oncol 34:369-74
Applebaum, Mark A; Jha, Aashish R; Kao, Clara et al. (2016) Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients. Oncotarget :
Pinto, Navin; Mayfield, Jodi R; Raca, Gordana et al. (2016) Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence. Pediatr Blood Cancer 63:1019-23
Sweis, Randy F; Spranger, Stefani; Bao, Riyue et al. (2016) Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res 4:563-8
Morrison, Gladys; Lenkala, Divya; LaCroix, Bonnie et al. (2016) Utility of patient-derived lymphoblastoid cell lines as an ex vivo capecitabine sensitivity prediction model for breast cancer patients. Oncotarget 7:38359-38366
Pettit, Kristen; Odenike, Olatoyosi (2016) Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches. Expert Rev Hematol :1-9
Brewer, Jamie R; Morrison, Gladys; Dolan, M Eileen et al. (2016) Chemotherapy-induced peripheral neuropathy: Current status and progress. Gynecol Oncol 140:176-83

Showing the most recent 10 out of 91 publications